Table 3.
Subpopulation analysis of estimated median survival and survival percentages.
| Variable | N (%) | Median survival (95% CI) in months | Overall survival (%) | P value | |||
|---|---|---|---|---|---|---|---|
| 12 months | 18 months | 36 months | 60 months | ||||
| MGMT | .339 | ||||||
| Methylated | 14 (32.5) | 9 (-) | 47 | 47 | 47 | NR | |
| Unmethylated | 29 (67.4) | 19 (13.8-24.1) | 77 | 55 | 28 | NR | |
| IDH | .254 | ||||||
| Wildtype | 59 (90.7) | 17 (5.5-28.4) | 58 | 48 | 43 | NR | |
| Mutant | 6 (9.2) | NR | 75 | 75 | NR | NR | |
| Age | <.001 | ||||||
| ≥60 years | 61 (41.7) | 6 (3.1-8.8) | 40 | 25 | 12 | NR | |
| <60 years | 85 (58.2) | 20 (14-25.9) | 77 | 57 | 43 | 14 | |
| Gender | .431 | ||||||
| Males | 80 (54.7) | 17 (13.6-20.3) | 58 | 38 | 21 | NR | |
| Females | 66 (45.2) | 10 (1.7-18.2) | 47 | 37 | 24 | 9 | |
| Resection extent | .003 | ||||||
| Biopsy | 47 (32.1) | 4 (1-13.4) | 40 | 9 | NR | NR | |
| Subtotal resection | 99 (67.8) | 18 (12.8-23.1) | 55 | 45 | 28 | 12 | |
| Adjuvant therapy | <.001 | ||||||
| None | 66 (45.2) | 3 (1.5-4.4) | 17 | 12 | 12 | NR | |
| Radiotherapy | 15 (10.2) | 6 (2.6-9.3) | 40 | 15 | NR | NR | |
| Radiotherapy + Temozolomide | 65 (44.5) | 25 (19-30.9) | 85 | 78 | 38 | 15 | |
NR: Not Reached; MGMT: O6-methylguanine-DNA methyltransferase; IDH: isocitrate dehydrogenase. Statistical analysis by the log-rank test.